Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). - Wikidata - awgldk - TriplyDB

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).

http://www.wikidata.org/entity/Q33783068

about

Concurrent chemoradiation for high-risk prostate cancer The cost of anal cancer in England: retrospective hospital data analysis and Markov model.Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.One compared with two cycles of mitomycin C in chemoradiotherapy for anal cancer: analysis of outcomes and toxicity.Chemoradiation as definitive treatment for primary squamous cell cancer of the rectum.Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm?Anal cancer treatment: current status and future perspectives.Interstitial high-dose rate brachytherapy as boost for anal canal cancer.HIV- positive anal cancer: an update for the clinician Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review.Radiochemotherapy in Anal Cancer: cCR, clinical outcomes and quality of life using two different treatment schedules Neoplasms of anal canal and perianal skin.Intensity-Modulated Radiotherapy (IMRT) vs Helical Tomotherapy (HT) in Concurrent Chemoradiotherapy (CRT) for Patients with Anal Canal Carcinoma (ACC): an analysis of dose distribution and toxicities.The differential diagnosis and interdisciplinary treatment of anal carcinoma French multicentre clinical evaluation of helical TomoTherapy for anal cancer in a cohort of 64 consecutive patients Intensified intensity-modulated radiotherapy in anal cancer with prevalent HPV p16 positivity Impact of facility volume on outcomes in patients with squamous cell carcinoma of the anal canal: Analysis of the National Cancer Data Base.Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies Long-term outcomes of chemoradiation for anal cancer patients.Chemoradiotherapy in squamous cell carcinoma of the anal canal: a single institution experience.Sphincter preservation in anal cancer: a brief review.Management of nodal recurrences of endometrial cancer with IMRT ACR Appropriateness Criteria®-Anal Cancer.Chemoradiotherapy with Brachytherapy or Electron Therapy Boost for Locally Advanced Squamous Cell Carcinoma of the Anus-Reducing the Colostomy Rate.Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.Update on treatment advances in combined-modality therapy for anal and rectal carcinomas.Optimal management of squamous cell carcinoma of the anal canal: where are we now?Optimal treatment strategies for anal cancer.Radio-chemotherapy in anal cancer: Institutional experience at a large radiation oncology center in Chile.Shifting paradigm in the management of anal canal carcinoma.Anal cancer: current standards in care and recent changes in practice.Investigational drugs for treating anal cancer and future perspectives.Pharmacotherapy of Anal Cancer.Chemoradiotherapy for squamous cell anal carcinoma: a review of prognostic factors.Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: back to the roots?Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer.Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial.The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed.

P2860

Q26798912-DBFD70E6-4BB0-45D4-AB8E-85B25D5AD688 Q30866180-550B15F1-C706-40AF-9351-1E24FF7B5527 Q33646367-F44E2BB3-445A-4F87-BE3F-FFC45C4691C9 Q33729819-3B29800F-E9C2-4970-A7E2-A3509DA80B7B Q33763918-4769EAE7-BE6A-4278-9416-AE7A6E7CA0BF Q33772521-44E26F69-9B5C-4ED6-8FA7-CD84783446A6 Q34276791-7ADA2C1E-8D71-406F-9390-2A116A0B0C25 Q34465769-32628663-0060-490D-8FAE-28EB9FA9B2EB Q34499551-F667431C-674A-4E73-BCB8-A0AB283C718A Q34640551-499D5288-E90A-4040-89D8-5519F85BED77 Q35086388-00591E22-0128-4509-97F8-F82D245FE719 Q35113390-1E742484-AADB-457D-8C20-59189356E7B6 Q35117964-85CF6CBC-DFD8-4253-8BE2-DB6246ED9E01 Q35530203-43F7604A-467C-4E4C-BE4A-8917DA735A5C Q35548994-0C25D41D-2EFB-4EA2-AD5E-0F29DF1E9814 Q36009950-AF11E394-2B8F-454B-9FA9-5E8CF294510A Q36105656-6771416E-181C-454B-9938-4D942ABE05C0 Q36115829-244943C7-9DA1-44BC-96B8-447DE4B2FDF5 Q36244369-9B19E9D8-6F88-4D16-B45E-F1BEF36E9BCA Q36299072-6B92DAB5-17DC-490E-B2E7-92CB94E3D39D Q36463914-ADA67B4E-91E5-44ED-B8E3-BC701E45760E Q36786775-1BB02F83-B42D-4E01-9780-63A18E546845 Q37005884-9C84EE8E-EC41-4C53-BE6E-1C833D57CF48 Q37025688-3ACFF2A5-FCB1-4491-9284-436A090D970B Q37584860-ECB29F8B-972F-45F5-9F02-5AD07376DE8A Q37643411-671B10DA-C3B0-42A4-8B6F-A7507B37BB95 Q37681208-500280F4-9915-49C1-8966-17C681A1983D Q37861572-6693EF4B-080E-403F-BCE5-8805286F5E5E Q38225033-65F71CC0-838E-48DB-9944-33514B2B2574 Q38227802-D22B00DC-B0EE-487D-99AE-86D36DC7CB28 Q38233873-3833C588-131B-4029-BE18-1CDCE934930F Q38272464-7859F8F5-53AB-4E8B-89FE-3499D3D1AAE0 Q38315952-872B50D6-3654-4397-9C74-74C800A8F19E Q38631415-56C0DA5A-20F5-4D7A-8A9F-873735ADEA7E Q38647761-E2FFC880-99E3-4A82-AA65-ED1D326603CA Q38793604-723791A8-C985-4BC3-868F-CC3391774A01 Q38970764-CCD99572-56B4-4A9A-940D-D55FE0604F6C Q39020800-9740EFD5-B8F1-4A47-BE7A-E208466CD438 Q39034562-49437244-11B0-4B75-9096-02BB9214BD79 Q39233316-9BFF80F5-F7E6-49AE-8CF5-094D6C84E56F

P2860

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I).

http://www.wikidata.org/entity/Q33783068

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Chemoradiation for the treatme ...... CCR Anal Cancer Trial (ACT I).

@ast

Chemoradiation for the treatme ...... CCR Anal Cancer Trial (ACT I).

@en

Chemoradiation for the treatme ...... CCR Anal Cancer Trial (ACT I).

@en-gb

type

label

Chemoradiation for the treatme ...... CCR Anal Cancer Trial (ACT I).

@ast

Chemoradiation for the treatme ...... CCR Anal Cancer Trial (ACT I).

@en

Chemoradiation for the treatme ...... CCR Anal Cancer Trial (ACT I).

@en-gb

prefLabel

Chemoradiation for the treatme ...... CCR Anal Cancer Trial (ACT I).

@ast

Chemoradiation for the treatme ...... CCR Anal Cancer Trial (ACT I).

@en

Chemoradiation for the treatme ...... CCR Anal Cancer Trial (ACT I).

@en-gb

P1433

Q33783068-9D1D5136-48FE-43AA-9BD6-277F34FE1F3D

P1476

Q33783068-D128D8B5-0102-4ADF-9F47-D264742775C6

P2093

Q33783068-19904963-3025-4798-A431-F687B6107D4B

Q33783068-37335EAD-EB23-4C76-8693-365B9129367A

Q33783068-56B1A70E-871D-4F14-8C03-68625C881259

Q33783068-619C8656-9997-420A-AC0F-77E2B2DC4ABF

Q33783068-C437F387-EC58-4265-A608-0E2A1F481B34

Q33783068-F399D542-F079-45CF-8A5A-AEB4A233DFC3

Q33783068-F7DBE9E3-3F90-4C9C-8C66-50FCE3D8F09C

P2860

Q33783068-068ABF89-5EAD-4689-857C-E0327980DEAA

Q33783068-0E0D84EE-A1F0-407B-8FB8-5084472480D9

Q33783068-13FB543B-1A89-4562-B04C-86B5C292F57F

Q33783068-44F8F2EF-F5BB-4537-96E6-1825248138A1

Q33783068-5CDEE3F1-ED8E-40AB-B2AB-581011E06F5C

Q33783068-5F50A5EE-BC5F-4429-B25E-1B1D8437622E

Q33783068-6F462769-A5EC-468D-B6E7-4D9A53730A2C

Q33783068-8FE73479-C38B-48C0-82BD-916C5C03EF3A

Q33783068-F18EEBA3-8DF4-4846-89F9-955D9556F052

P2888

Q33783068-18988A02-7A07-44D2-B52E-78032F1163CF

P304

Q33783068-AD6099C2-0707-46B4-B4CB-CBADEF84D842

P31

Q33783068-7FC2FF39-0C64-4AE4-B022-F385AB0AA5C3

P356

Q33783068-E55716B4-11CC-4DA5-853A-4BB1C02D4F7B

P407

Q33783068-BE8FA63F-07AE-4B4D-9610-6ACE3AA788D0

P433

Q33783068-13F08791-4D71-4663-A113-B384B8718C16

P478

Q33783068-2522D6C3-E926-4DDF-8A6B-9B6EB4BFBF28

P50

Q33783068-06A8246B-CE85-46A4-A127-6938B1F9B641

P577

Q33783068-315180F1-D5BD-420F-987B-F9A41B617A54

P5875

Q33783068-12086E0F-81F7-44D7-ADD5-7C300AF8BDED

P6179

Q33783068-6C435B0C-F9CB-45DB-89FC-391DE0F20202

P698

Q33783068-D366E3F3-96D3-45DD-A259-7FC9F02759A2

P921

Q33783068-E066F04C-EA44-4FA0-9380-514A859A0532

P932

Q33783068-83C1145C-2AE9-4143-B2F6-D5D1B5DDDED2

P356

P1433

British Journal of Cancer

P1476

Chemoradiation for the treatme ...... CCR Anal Cancer Trial (ACT I).

@en

P2093

H Meadows

http://www.w3.org/2001/XMLSchema#string

J Ledermann

http://www.w3.org/2001/XMLSchema#string

J Northover

http://www.w3.org/2001/XMLSchema#string

M Jitlal

http://www.w3.org/2001/XMLSchema#string

R Glynne-Jones

http://www.w3.org/2001/XMLSchema#string

R James

http://www.w3.org/2001/XMLSchema#string

S Wan

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2009

Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review.

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Cardiovascular toxicity associated with cancer treatment.

Vascular complications of selected cancer therapies.

Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.

Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer.

Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.

Tobacco smoking as a risk factor in anal carcinoma: an antiestrogenic mechanism?

P2888

P304

1123-1128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605605

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

David Sebag-Montefiore

P577

2010-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42768709

http://www.w3.org/2001/XMLSchema#string

P6179

1019439492

http://www.w3.org/2001/XMLSchema#string

P698

20354531

http://www.w3.org/2001/XMLSchema#string

P921

chemoradiotherapy

P932

2853094

http://www.w3.org/2001/XMLSchema#string